Core Insights - Ginkgo Bioworks is focusing on divesting its biosecurity business to redirect capital towards its autonomous labs strategy, which is expected to be a key growth area for the company in 2026 [1][6][7] Financial Performance - In Q4 2025, cell engineering revenue was $26 million, a 26% decline year-over-year, with full-year revenue at $133 million compared to $174 million in 2024 [5][9] - Cash burn improved significantly, falling to $171 million for 2025 from $383 million in 2024, with Q4 cash burn at $47 million, down from $55 million in Q4 2024 [16] - Total Adjusted EBITDA was -$36 million in Q4 2025, an improvement from -$57 million in Q4 2024, and for the full year, it was -$167 million compared to -$293 million in 2024 [15] Strategic Focus - The company plans to transition work from traditional lab setups to a single large autonomous lab in Boston, aiming to enhance efficiency and scalability [2][7] - Ginkgo aims to expand its autonomous lab capacity to 100 racks and integrate advanced AI technologies, such as GPT-5, into its operations [7][18] Future Guidance - For 2026, Ginkgo will not provide revenue guidance but will focus on cash burn, estimating it to be between $125 million and $150 million, reflecting ongoing investments in autonomous labs [17] - The company is prioritizing long-term investments over short-term revenue generation, emphasizing the importance of cash deployment in its strategic initiatives [17] Operational Developments - Ginkgo is actively working on enhancing its autonomous lab capabilities, including a new $47 million contract with the Department of Energy to build a 97-robot, 97-rack autonomous lab [25] - The company has hosted tours of its Nebula autonomous lab, which currently has over 50 racks, with plans to expand to 100 racks by mid-2026 [25]

Financial Performance - Ginkgo's Q3 2025 total revenue was $39 million, a decrease of 56% year-over-year compared to $89 million in Q3 2024[34] - Cell Engineering revenue in Q3 2025 was $29 million, a 61% decrease compared to $75 million in Q3 2024, which includes $45 million of non-cash deferred revenue from Motif[23, 34] - Biosecurity revenue in Q3 2025 was $9 million, a 32% decrease compared to $14 million in Q3 2024[34] - Total Adjusted EBITDA for Q3 2025 was $(56) million, compared to $(20) million in Q3 2024[34] - Ginkgo reaffirms its full year 2025 total revenue guidance of $167-187 million[43] - Ginkgo's cash, cash equivalents, and marketable securities remain strong at $462 million as of Q3 2025[17] - Quarterly cash burn continues to improve, with a 73% decrease from the prior quarter[14] Strategic Focus - Ginkgo is expanding its business model into life science tools and services[54, 96] - Ginkgo believes AI models will impact biotechnology in two ways and is well-positioned to provide tools in both[48, 51, 93, 115] - Ginkgo continues to offer research solutions on top of its in-house robotics, winning new deals in Agriculture and with the US Government[49, 52, 94, 116] - Ginkgo is expanding its frontier autonomous lab in Boston as a showcase[50, 53, 95, 117, 118]